6446:TWSEPharmaEssentia Corp. Analysis

PharmaEssentia is trading at TWD 670, which sits below its 20‑day SMA of 714.95 but above the 50‑day SMA of 616.87, suggesting a short‑term pull‑back within a broader up‑trend (200‑day SMA 517.9). The RSI of 48.3 indicates the stock is neither overbought nor oversold, while the MACD shows a bearish divergence (histogram –13.34) that could pressure prices in the near term. Volume is increasing, supporting the bullish trend direction, yet volatility remains high at 61% over the past 30 days, and beta around 0.8 points to moderate market sensitivity. Fundamentals are robust: revenue surged 59% YoY, gross margin exceeds 89%, and operating cash flow surpasses TWD 5.3 bn, while debt is modest relative to cash reserves. However, valuation metrics are stretched – the trailing P/E of 49 is double the industry average of 25, and the DCF‑derived fair value (~TWD 278) is far below the current price, implying a significant overvaluation. The pipeline of oncology and hematology therapies offers long‑term upside, but regulatory approval risk and the current premium price cap near‑term upside potential.